Damora Therapeutics Appoints Biotech Veteran Jennifer Jarrett as CEO, Strengthens Board with Key Industry Leaders

summarizeSummary

Damora Therapeutics announced the appointment of Jennifer Jarrett, a seasoned biotech and finance executive, as its new President and CEO, effective March 30, 2026. The company also significantly strengthened its Board of Directors with two new appointments and named a new Chairman, positioning itself for its recently announced strategic pivot.

check_boxKey Events

• New CEO Appointed

  Jennifer Jarrett, a veteran biotech and finance executive with experience from Arcus Biosciences and Medivation, has been named President and Chief Executive Officer, effective March 30, 2026. She also joins the Board of Directors.

• Board Strengthened with Industry Veterans

  Michael Landsittel, former CFO of Blueprint Medicines, and Cameron Turtle, current CEO of Spyre Therapeutics, were appointed as new Class III directors, bringing significant financial and operational expertise.

• New Board Chairman Named

  Peter Harwin, a current director, has been appointed Chairman of the Board of Directors, consolidating leadership.

• Leadership Transition Details

  Current CEO Sherwin Sattarzadeh will transition to Chief Operating Officer, retaining institutional knowledge within the company.

auto_awesomeAnalysis

This 8-K details a critical leadership transition for Damora Therapeutics, following its recent strategic pivot and substantial capital raise. The appointment of Jennifer Jarrett as President and CEO, with her extensive background in oncology drug development, corporate strategy, and finance from companies like Arcus Biosciences and Medivation, is a strong positive signal. Her experience is highly relevant for a biotechnology company aiming to advance a new pipeline. The simultaneous appointment of Michael Landsittel (former CFO of Blueprint Medicines, known for significant capital raises) and Cameron Turtle (CEO of Spyre Therapeutics) to the Board of Directors further enhances the company's strategic and financial expertise. These changes are crucial for executing the company's new direction in mutCALR-driven myeloproliferative neoplasms and effectively deploying its recently secured capital. While three directors resigned, the company stated it was not due to disagreements, and the new appointments appear to be a strategic upgrade. The retention of the General Counsel also provides stability. Investors should view this as a significant step towards solidifying leadership for future growth and execution.